Johnson & Johnson's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Operating-Income" stands at 26.26 Billion United States Dollars for the trailing twelve months (TTM) period ending 06/30/2026, the highest value at least since 12/31/2012, the period currently displayed.
Johnson & Johnson's second quarter result of 7.17 Billion USD for the item "Operating Income" represents an increase of 12.18 percent compared to it's first quarter result.
Also, Johnson & Johnson's second quarter result of 7.17 Billion USD for the item "Operating Income" represents an increase of 5.35 percent compared to it's second quarter result of last year.
Looking again at the trailing twelve months series (TTM), Johnson & Johnson's second quarter result of 26.26 Billion USD for the item "Operating Income" represents an increase of 1.41 percent compared to it's first quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 18.12 percent compared to the value the year prior.
The 1 year change in percent is 18.12.
The 3 year change in percent is 17.58.
The 5 year change in percent is 12.60.
The 10 year change in percent is 36.86.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Operating Income | 905,699,262,464.00 |
![]() | AbbVie Inc - Operating Income | 399,570,305,024.00 |
![]() | Roche Holding AG - Operating Income | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Operating Income | 280,205,508,085.11 |
![]() | Novartis AG - Operating Income | 255,096,620,580.91 |